U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07516288) titled 'Safety and Efficacy of Second Infusion of FAP iCDC in End-stage Dilated Cardiomyopathy' on March 24.
Brief Summary: This study aims to evaluate the safety and preliminary efficacy of a second administration of fibroblast activation protein (FAP)-targeted immunosuppressive chimeric antigen receptor dendritic cells (CAR-DC) in patients with end-stage dilated cardiomyopathy.
Previous clinical research has shown that single-dose CAR-DC therapy is safe and may provide clinical benefit. However, some patients experience recurrent worsening of heart function after initial treatment. This study will assess whether a second CAR-DC infusion ...